Combined modality management of breast cancer: development of predictive markers through proteomics.

Chakravarthy B, Pietenpol JA
Semin Oncol. 2003 30 (4 Suppl 9): 23-36

PMID: 12908134 · DOI:10.1016/s0093-7754(03)00267-7

MeSH Terms (14)

Antineoplastic Agents Biomarkers, Tumor Breast Neoplasms Combined Modality Therapy Female Forecasting Humans Neoadjuvant Therapy Prognosis Prospective Studies Proteomics Remission Induction Retrospective Studies Survival Rate

Connections (1)

This publication is referenced by other Labnodes entities: